

## Claims

1. Use of a GLP-1 agonist for the manufacture of a medicament for lowering total serum lip-  
ids.
- 5 2. Use of a GLP-1 agonist for the manufacture of a medicament for lowering LDL.
3. Use of a GLP-1 agonist for the manufacture of a medicament for lowering smal, dense  
LDL
- 10 4. Use of a GLP-1 agonist for the manufacture of a medicament for lowering VLDL.
5. Use of a GLP-1 agonist for the manufacture of a medicament for lowering triglycerides.
- 15 6. Use of a GLP-1 agonist for the manufacture of a medicament for lowering cholesterol.
7. Use of a GLP-1 agonist for the manufacture of a medicament for increasing HDL.
8. Use of a GLP-1 agonist for the manufacture of a medicament for lowering plasma levels of  
20 Lp(a) in a human.
9. Use of a GLP-1 agonist for the manufacture of a medicament for inhibiting generation of  
apo(a) in a human.
- 25 10. Use of a GLP-1 agonist for the manufacture of a medicament for treating dyslipidemia.
11. The use according to any one of claims 1-10 wherein the GLP-1 agonist binds to a GLP-1  
receptor with an affinity constant,  $K_D$ , below 1  $\mu M$ .
- 30 12. The use according to any one of claims 1-11 wherein the GLP-1 agonist is selected from  
Arg<sup>26</sup>, Lys<sup>34</sup>(N- $\epsilon$ -( $\gamma$ -Glu(N- $\alpha$ -hexadecanoyl)))-GLP-1(7-37), Arg<sup>34</sup>, Lys<sup>26</sup>(N- $\epsilon$ -( $\gamma$ -Glu(N- $\alpha$ -  
hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, Val<sup>8</sup>-GLP-1(7-37), Thr<sup>8</sup>- GLP-1(7-37),  
Met<sup>8</sup>- GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-37).

13. A method of lowering total serum lipids, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

14. A method of lowering LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

15. A method of lowering small, dense LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

16. A method of lowering VLDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

17. A method of lowering triglycerides, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

18. A method of lowering cholesterol, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

19. A method of increasing HDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

20. A method of inhibiting generation of apo(a) in vitro or in vivo by administering a GLP-1 agonist.

21. A method of lowering plasma levels of Lp(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.

22. A method of inhibiting generation of apo(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.

23. A method for treating dyslipidaemia which method comprises administering to a subject an effective amount of a GLP-1 agonist.

24. The method according to any one of claims 13-23 wherein the GLP-1 agonist binds to a GLP-1 receptor with an affinity constant,  $K_D$ , below 1  $\mu$ M.

25. The method according to any one of claims 13-23 wherein the GLP-1 agonist is selected from Arg<sup>26</sup>, Lys<sup>34</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), Arg<sup>34</sup>, Lys<sup>26</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, Val<sup>8</sup>-GLP-1(7-37), Thr<sup>8</sup>-GLP-1(7-37),  
5 Met<sup>8</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-37).